-+ 0.00%
-+ 0.00%
-+ 0.00%

Scribe Therapeutics' STX-1150 prototype lowers LDL-C over 50% for two years in primate study

PUBT·11/18/2026 13:06:20
Scribe Therapeutics' STX-1150 prototype lowers LDL-C over 50% for two years in primate study
  • Scribe Therapeutics presented updated preclinical cardiovascular treatment data at the American Heart Association Scientific Sessions on Nov. 18, 2026.
  • A single STX-1150 prototype dose produced sustained LDL cholesterol lowering in nonhuman primates without permanent DNA modification; repeat dosing deepened reductions.
  • No off-target changes were detected for STX-1150; a toxicology study found no treatment-related adverse findings.
  • An STX-1200 surrogate substantially reduced lipoprotein(a) in nonhuman primates; testing in primary human liver cells detected no off-target editing.
  • STX-1150 is in a first-in-human trial, with initial Phase 1 single-dose data expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180800PRIMZONEFULLFEED9880027) on November 18, 2026, and is solely responsible for the information contained therein.